Agios Presents Positive Results From Phase 3 ENERGIZE-T Study Of Mitapivat At ASH 2024 And Provides Regulatory Update On Mitapivat
Agios Presents Positive Results From Phase 3 ENERGIZE-T Study Of Mitapivat At ASH 2024 And Provides Regulatory Update On Mitapivat . (MENAFN - EIN Presswire) 
 
  – ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108969080/Agios-Presents-Positive-Results-From-Phase-3-ENERGIZE-T-Study-Of-Mitapivat-At-ASH-2024-And-Provides-Regulatory-Update-On-Mitapivat
2024-12-08
rss
(MENAFN - EIN Presswire) 
 
  – ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First ...
Agios Presents Positive Results From Phase 3 ENERGIZE-T Study Of Mitapivat At ASH 2024 And Provides Regulatory Update On Mitapivat